What is Ainos?
Founded in 1984 and headquartered in San Diego, California, Ainos operates at the intersection of diagnostics and therapeutics. The company is dedicated to advancing novel point-of-care testing, developing low-dose interferon therapeutics, and pioneering synthetic RNA-driven preventative medicine. This multi-faceted strategy positions Ainos as a key player in addressing diverse healthcare needs through technological innovation.
How much funding has Ainos raised?
Ainos has raised a total of $12.8M across 3 funding rounds:
Stock Offering
$3.2M
Debt
$600K
Share Placement
$9M
Stock Issuance/Offering (2008): $3.2M, investors not publicly disclosed
Debt (2016): $600K, investors not publicly disclosed
Share Placement (2024): $9M, investors not publicly disclosed
What's next for Ainos?
With a substantial enterprise-level funding context and a recent strategic investment, Ainos is poised for significant expansion. The company's focus on point-of-care diagnostics and advanced therapeutic modalities, including synthetic RNA, suggests a strategic push towards commercialization and market penetration. Future developments are likely to center on scaling production, expanding clinical trials, and forging strategic partnerships to bring its innovative medical technologies to a wider audience.
See full Ainos company page
